Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2456

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2456). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622456)

This is a package insert for Lisdexamfetamine dimesylate 50 mg capsules, equivalent to 28.9 mg of lisdexamfetamine. It provides information on dosage and storage conditions, and includes details for pharmacists on dispensing the medication to patients. The medication guide and manufacturer information are also included.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

FDA Label Image

Figure 1 (Lisdexcaps 02)

This text provides information about a special population categorized by gender (Male/Female) and age groups (65 years and above). It also includes different levels of renal impairment such as mild, moderate, severe, and end-stage renal disease. Additionally, it mentions fold change and 90% CI related to a reference point.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

FDA Label Image

Figure 3 (Lisdexcaps 04)

This is not readable text.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

This text provides information about LS Mean (SE) SKAMP Deportment Scores for Placebo and Lisdexamfetamine over time post-dose. The data appears to be showing scores at 0, 2, and 5 hours post-dose for both treatment groups. The text does not provide a full description but gives a glimpse into a study or experiment comparing the two treatments for SKAMP Deportment Scores.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

FDA Label Image

Figure 6 (Lisdexcaps 07)

This text provides information about LS Mean (SE) PERMP Total Scores for both Phacebo and Lisdexamfetamine over a period of time post-dose (hours). The scores range from 330 to 250 with time points at 4, 8, 12, and 14 hours post-dose. It seems to be a numerical data table related to the evaluation of the two treatments.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

This is a data table showing the proportion of subjects with relapse/treatment failure over time (days after randomization) for lisdexamfetamine.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.